



PRESS RELEASE

University Hospital Center of Grenoble Alpes (CHUGA) becomes the 20th University Hospital equipped with the EOS[®] system in France

The equipment will be dedicated to pediatric and adult care and to the development of innovative orthopedic treatments

Paris, July 3, 2018 – EOS imaging (Euronext, FR0011191766 - EOSI - Eligible PEA - PME), the pioneer of 2D/3D imaging and data solutions for orthopedics, today announced the installation of its EOS[®] system at the University Hospital Center of Grenoble Alps (CHUGA), a state-of-the-art hospital facility for osteoarticular surgery in children and adults. CHUGA is the 20th university hospital center to acquire an EOS[®] system, and the new system will be dedicated to the center's clinic as well as to clinical research activities.

With more than 2,100 beds, CHUGA employs nearly 8,000 professionals, including 1,700 doctors. It has an advanced technical platform and provides highly specialized care. The center's teams are recognized for their excellence in orthopedic surgery, particularly in the field of advanced surgical techniques assisted by navigation or robotics.

The new EOS system will be located in the pediatric radiology department within the pediatric section of the hospital. It will be used in the care of both pediatric and adult patients through a collaboration with two adult orthopedic services located in the North and South Poles of CHUGA.

"The EOS system will allow us to further develop the clinical care of our pediatric patients through imaging at low radiation dose. It will also significantly accelerate our collaborative research programs with EOS on the orthopedic treatment of scoliosis with braces," commented Professor Aurélien Courvoisier, Pediatric Orthopedic Surgeon.

"We are very pleased to serve the Grenoble Hospital Center for clinical and research applications," commented Marie Meynadier, Chief Executive Officer of EOS imaging. *"The patient has always been our main concern as we work to spread low-dose, 2D/3D imaging capabilities. EOS has changed the care of osteo-articular pathologies and has become a standard thanks to lower radiation, higher accuracy, and 3D imaging of the full body, all of them valuable in choosing the most effective treatments, preparing surgical intervention, as well as in post-operative follow-up. On the research side, we hope to open new perspectives on the treatment of spinal deformities with braces, and will also pursue collaborative programs on the integration of the EOS examination data in the operating room."*

About EOS imaging

EOS imaging designs, develops and markets EOS[®], a major innovative medical imaging solution dedicated to osteoarticular pathologies and orthopedics combining equipment and services and targeting a \$2B per year market opportunity. EOS imaging is currently present in 31 countries, including the United States under FDA agreement, Japan, China and the European Union under CE labelling, through the over 250 installed EOS[®] platforms representing around one million patient exams every year. Revenues were €37.1M in 2017, e.g. a +32% CAGR over 2012-2017.



PRESS RELEASE

For more information, please visit www.eos-imaging.com.

EOS imaging has been selected to integrate the EnterNext © PEA - PME 150 index, composed of 150 French, listed companies on the Euronext markets in Paris.

EOS imaging is listed on Compartment C of Euronext Paris
ISIN: FR0011191766 - Ticker: EOSI



Contacts:

EOS imaging

Marie Meynadier
CEO

Ph: +33 (0)1 55 25 60 60

investors@eos-imaging.com

Press Relations (US)

Joanna Zimmerman
The Ruth Group

Ph: 646-536-7006

jzimmerman@theruthgroup.com

Investor Relations (US)

Matt Picciano / Emma Poalillo
The Ruth Group

Ph: 646-536-7008 / 7024

EOS-imagingIR@theruthgroup.com